ReviewToxins2026
Factors Beyond High-Molecular-Weight Toxin Removal That Might Affect Survival in Comparisons of High-Volume Hemodiafiltration with Hemodialysis.
Review in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comparisons of hemodiafiltration with hemodialysis have indicated significantly improved survival when the substitution fluid volume is greater than 23 L per treatment. This survival benefit has been ascribed to better removal of high-molecular-weight uremic toxins. However, with hemodiafiltration, predialysis levels of some high-molecular-weight toxins are only modestly reduced and remain far above levels measured in subjects with normal kidney function. In the present review, the potential role of other factors associated with hemodiafiltration that may beneficially impact survival relative to that seen with hemodialysis is explored. Factors analyzed include removal of relatively small uremic toxins such as urea, phosphate, and oxalate, a reduced incidence of intradialytic hypotension in some studies, possibly related to lower extracorporeal circuit temperature, benefits associated with use of ultrapure dialysis solution, and potential benefits associated with avoidance of thrice-weekly saline infusion for priming, volume replacement, and rinse back. The survival benefit associated with each of these factors may be small, but collectively, they may have a clinical impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.